Although most MS DMDs affect the immune system, some of them also affect the neurodegenerative metabolic pathways, e.g., the nuclear factor erythroid-2-related factor 2 (NRF2)-Kelch-like ECH-associated protein 1 (KEAP1) signaling, an enzyme involved in the pathogenesis of MS [14]. Here, KEAP1 is linked to myeloid sarcoma.